 Your new post is loading...
Your new post is loading...
|
Scooped by
Gilbert C FAURE
August 23, 2012 2:58 AM
|
RT @BlackpoolHosp: Great news today as our top quality haematology service has been recognised with JACIE accreditation.
|
|
Scooped by
Gilbert C FAURE
August 22, 2012 2:55 PM
|
Cell Type Proposed as Insulin-Producing ProgenitorGenetic Engineering NewsThe potential to one day treat type 1 diabetes using transplants of insulin-producing beta-cells derived from pancreatic progenitors may have just crept a tad closer, if findings...
|
|
Scooped by
Gilbert C FAURE
August 22, 2012 2:51 PM
|
Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody.
|
|
Scooped by
Gilbert C FAURE
August 22, 2012 2:49 PM
|
Symphogen Publishes Final Rozrolimupab (SYM001) Phase 2 Trial Results in ...MarketWatch (press release)Symphogen develops antibody therapeutics (mixtures of monoclonal antibodies) to help people with serious diseases and significant unmet medical...
|
|
Scooped by
Gilbert C FAURE
August 21, 2012 3:54 AM
|
ScienceDaily (Aug.(Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis http://t.co/nq1mc4nT...)...
|
|
Scooped by
Gilbert C FAURE
August 21, 2012 3:51 AM
|
Juventas Therapeutics doses first patient in Phase II STOP-HF trialSacramento Bee"We established the Company based on a hypothesis that cell therapy could be distilled down to factor-based approaches, which would be clinically-beneficial while reducing...
|
|
Scooped by
Gilbert C FAURE
August 21, 2012 3:29 AM
|
Ensuring Reliable Scale-up of Biopharmaceutical ProductionPharmaceutical ProcessingDemand for biopharmaceuticals, especially monoclonal antibody-related products, continues to grow at a very healthy pace with total biopharmaceutical sales reaching...
|
|
Scooped by
Gilbert C FAURE
August 21, 2012 3:15 AM
|
Biomarkers and immune-modulating therapies for Type 2 diabetes: Recent advances in understanding the etiology of...
|
|
Scooped by
Gilbert C FAURE
August 20, 2012 2:01 PM
|
A self-assembling nanoparticle designed to target tumour cells like a virus was unveiled today. Read more (RT @shervin: very cool “@zeigor: “A self-assembling nanoparticle designed to target tumour cells like a virus was unveiled today.”...
|
|
Scooped by
Gilbert C FAURE
August 20, 2012 1:41 PM
|
|
|
Scooped by
Gilbert C FAURE
August 20, 2012 1:37 PM
|
Abstract Current therapies for systemic lupus erythematosus (SLE), a debilitating, potentially lethal, multifactorial systemic autoimmune disease, are limited to suppressing disease activity and are associated with multiple adverse effects.
|
|
Scooped by
Gilbert C FAURE
August 19, 2012 12:42 PM
|
Abstract. A major goal of tumor immunotherapy is the induction of long-lasting systemic T-cell immunity. Bispecific antibodies (bsAbs) that lack the immunoglobulin Fc region confer T–cell-mediated killing of tumor cells but do ...
|
|
Scooped by
Gilbert C FAURE
August 19, 2012 12:30 PM
|
Merck, Arrowhead to evaluate antibody candidatePharmaceutical Business ReviewArrowhead Research Corporation and Merck have entered into an agreement to evaluate a proprietary therapeutic monoclonal antibody candidate evolved from Arrowhead's...
|
|
|
Scooped by
Gilbert C FAURE
August 23, 2012 2:52 AM
|
Clinical Research Trial Listings for Sarcoidosis in Dermatology, Plastic Surgery Immunology, Infectious Diseases on CenterWatch (Immunology/Infectious #sarcoidosis - Studies: Israel|North Carolina|South Carolina|Ohio
|
|
Scooped by
Gilbert C FAURE
August 22, 2012 2:51 PM
|
MedImmune has announced a licensing agreement with Amgen for a new monoclonal antibody targeting IL-1 path. The antibody, AMG 108, a fully human monoclonal antibody to IL-1 receptor, has been studied in various ...
|
|
Scooped by
Gilbert C FAURE
August 22, 2012 2:50 PM
|
In addition, the monoclonal antibody is likely to be safer because it is cleared from the blood and is not retained in bone. Results from the study are published online August 20 in the journal Proceedings of the National ...
|
|
Scooped by
Gilbert C FAURE
August 21, 2012 2:26 PM
|
A better understanding of the immunological mechanisms underpinning existing and novel vaccines is therefore required. Fortunately, research efforts to uncover new molecular and cellular techniques offer exceptional ...
|
|
Scooped by
Gilbert C FAURE
August 21, 2012 3:51 AM
|
Genetic Engineering NewsOncogene Addiction: Real or Not?Genetic Engineering NewsCan cancer cells' “addiction” to a specific oncogene be exploited to develop new therapies?
|
|
Scooped by
Gilbert C FAURE
August 21, 2012 3:50 AM
|
The House of Lords inquiry into regenerative medicine: mapping the UK route ...BioNewsThe UK House of Lords Science and Technology Select Committee (1) has launched an inquiry into cell therapy and regenerative medicine to take place this autumn.
|
|
Scooped by
Gilbert C FAURE
August 21, 2012 3:23 AM
|
Genzyme, a unit of Sanofi, said Monday it is withdrawing leukemia drug Campath to prepare for its possible launch in 2013 as a multiple sclerosis treatment that will be marketed as Lemtrada.
|
|
Scooped by
Gilbert C FAURE
August 20, 2012 2:10 PM
|
Pharmaceutical Industry | FEATURE | General | Antibody-drug conjugates on the up in cancer - Mylotarg served as a lesson of the pitfalls of ADCs: two years after it was pulled from the market some of the ADCs now in development will emerge as blockbusters...
|
|
Scooped by
Gilbert C FAURE
August 20, 2012 1:41 PM
|
AbGenomics obtains US FDA agreement for proposed AbGn-168H phase II trialpharmabiz.comIn SRD phase I psoriasis patient study, a clear biological/pharmacological effect consistent with the proposed mechanism of action of AbG's antibody was...
|
|
Scooped by
Gilbert C FAURE
August 20, 2012 1:39 PM
|
PubMed comprises more than 22 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
|
|
Scooped by
Gilbert C FAURE
August 20, 2012 2:43 AM
|
Celldex Therapeutics presents positive results of phase 2 study of antibody-conjugated drug product candidate CDX-011 in advanced breast cancer. Published August 19, 2012 | By admin. The Phase 2 study investigated the safety, tolerability ...
|
|
Scooped by
Gilbert C FAURE
August 19, 2012 12:33 PM
|
The anti-α4 monoclonal antibody natalizumab inhibits lymphocyte extravasation into the central nervous system and increases peripheral T and B lymphocytes in multiple sclerosis patients. To investigate whether the ...
|
Scoop.it!
